Difficulty: Medium
Average Score: 86%
Practice
Indicate the reversible cholinesterase inhibitor, which penetrates the blood-brain barrier:
Correct answer
A
Rationale
In the context of safety pharmacology across the lifespan, understanding the mechanisms of drugs that act on the cholinergic system is crucial. Physostigmine is the correct answer because it is a reversible cholinesterase inhibitor that can penetrate the blood-brain barrier. This property allows physostigmine to exert its effects centrally, making it useful in conditions like myasthenia gravis and overdose of anticholinergic medications.
Edrophonium, Pidrophonium, and Piridostigmine are incorrect choices for this question. Edrophonium is a short-acting cholinesterase inhibitor used for diagnostic purposes in conditions like myasthenia gravis but does not readily cross the blood-brain barrier. Pidrophonium and Piridostigmine are not commonly used drugs and do not possess the ability to penetrate the blood-brain barrier efficiently.
Educationally, this question highlights the importance of understanding the pharmacokinetic properties of drugs when considering their effects on the central nervous system. It underscores the significance of selecting the appropriate cholinesterase inhibitor based on its ability to cross the blood-brain barrier for conditions requiring central cholinergic modulation. This knowledge is essential for healthcare professionals involved in the management of patients across different age groups who may require pharmacological interventions targeting the cholinergic system.
Edrophonium, Pidrophonium, and Piridostigmine are incorrect choices for this question. Edrophonium is a short-acting cholinesterase inhibitor used for diagnostic purposes in conditions like myasthenia gravis but does not readily cross the blood-brain barrier. Pidrophonium and Piridostigmine are not commonly used drugs and do not possess the ability to penetrate the blood-brain barrier efficiently.
Educationally, this question highlights the importance of understanding the pharmacokinetic properties of drugs when considering their effects on the central nervous system. It underscores the significance of selecting the appropriate cholinesterase inhibitor based on its ability to cross the blood-brain barrier for conditions requiring central cholinergic modulation. This knowledge is essential for healthcare professionals involved in the management of patients across different age groups who may require pharmacological interventions targeting the cholinergic system.